Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.

B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236. The firm notes the erosion of ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...